Provided by Tiger Trade Technology Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.76
+0.04002.33%
Post-market: 1.780.0200+1.14%19:54 EST
Volume:1.62M
Turnover:2.88M
Market Cap:149.90M
PE:-2.23
High:1.80
Open:1.75
Low:1.75
Close:1.72
52wk High:3.06
52wk Low:0.6254
Shares:85.17M
Float Shares:78.81M
Volume Ratio:0.60
T/O Rate:2.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7900
EPS(LYR):-0.6674
ROE:-260.65%
ROA:-41.97%
PB:7.31
PE(LYR):-2.64

Loading ...

Milestone Pharmaceuticals Chief Medical Officer David Bharucha Reports Disposal of Common Shares

Reuters
·
Jan 29

Milestone Pharmaceuticals Inc - National Sales Force Deployment for Cardamyst Set for Mid-February 2026

THOMSON REUTERS
·
Jan 26

Milestone Pharmaceuticals Announces U.S. Availability of Cardamyst™ (Etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults With Paroxysmal Supraventricular Tachycardia (Psvt)

THOMSON REUTERS
·
Jan 26

Milestone Pharmaceuticals Inc - Copays for Eligible Insured Patients Expected to Be Capped at $25

THOMSON REUTERS
·
Jan 26

Milestone Pharmaceuticals CEO Joseph Oliveto Reports Disposal of Common Shares

Reuters
·
Jan 10

Milestone Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 07

EMA Accepts Milestone Pharmaceuticals' Application for Etripamil Nasal Spray in PSVT

Reuters
·
Jan 06

Milestone Pharmaceuticals Inc - European Approval Decision Expected by Q1 2027

THOMSON REUTERS
·
Jan 06

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in Psvt by the European Medicines Agency

THOMSON REUTERS
·
Jan 06

AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment

Reuters
·
Dec 18, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Brystol Myers, Nvidia

Reuters
·
Dec 16, 2025

Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 16, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Vanda Pharma, Tesla, Zillow

Reuters
·
Dec 15, 2025

Milestone Pharmaceuticals Inc : TD Cowen Raises to Buy From Hold

THOMSON REUTERS
·
Dec 15, 2025

Milestone Pharmaceuticals Inc. : H.c. Wainwright Raises Target Price to $8 From $5

THOMSON REUTERS
·
Dec 15, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Carvana, ServiceNow

Reuters
·
Dec 15, 2025

Shares of Milestone Pharmaceuticals up 34.8% Premarket After FDA Approves Co's Heart Rhythm Nasal Spray

THOMSON REUTERS
·
Dec 15, 2025

Milestone Pharmaceuticals Says US FDA Approves Cardamyst Spray for Supraventricular Tachycardia Episodes

MT Newswires Live
·
Dec 15, 2025

FDA Approves Milestone Pharmaceuticals’ CARDAMYST Nasal Spray for PSVT

Reuters
·
Dec 13, 2025

Milestone Receives FDA Approval of Cardamyst™ (Etripamil) as First and Only Self-Administered Nasal Spray for Adults With Paroxysmal Supraventricular Tachycardia (Psvt)

THOMSON REUTERS
·
Dec 13, 2025